Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 12/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487394 | 0.94 | PDK2 (0.41) | PDK2HTR2CBRD4DHODHKDM4E | |
| SCHEMBL13487102 | 0.93 | PDK2 (0.36) | PDK2HTR2CBRD4DHODHKDM4E | |
| SCHEMBL13487355 | 0.91 | PDK2 (0.34) | PDK2HTR2C | |
| SCHEMBL13488125 | 0.91 | PDK2 (0.44) | PDK2HTR2CBRD4DHODHKDM4E | |
| SCHEMBL13487273 | 0.90 | KDM4E (0.38) | PDK2HTR2CDHODHKDM4ENPC1 | |
| SCHEMBL13487356 | 0.89 | ALOX5AP (0.35) | PDK2 | |
| SCHEMBL13487170 | 0.89 | HTR2C (0.42) | PDK2HTR2CDHODHKDM4ENPC1 | |
| SCHEMBL13487360 | 0.88 | PDK2 (0.35) | PDK2 | |
| SCHEMBL13487759 | 0.87 | PDK2 (0.42) | PDK2HTR2CBRD4DHODHKDM4E | |
| SCHEMBL13487898 | 0.87 | PDK2 (0.42) | PDK2HTR2CBRD4DHODHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| EP-2108689-A2 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | PDK2 1456/4885HTR2C 4442/4885BRD4 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.